Avis et décisions de la HAS
La recommandation relative à la prise en charge à titre dérogatoire de l’infliximab (REMICADE) dans le cadre d’une recommandation temporaire d’utilisation, ci-jointe, est adoptée.
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
6umSRmjKW7ZRNjSW